Novartis Pharmaceutical Corporation
150 Industrial Road
40 articles with Novartis Pharmaceutical Corporation
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
In support of Lipoprotein(a) Awareness Day, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced a collaboration with Novartis Pharmaceuticals Corporation (Novartis) to increase awareness for Lipoprotein(a) (Lp(a)). High levels of Lp(a) are associated with increased risk of heart attack, stroke and other life threatening conditions.
Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence
Novartis Pharmaceuticals Corporation to collaborate on development of new medical device software for earlier detection and intervention in cardiovascular disease.
The FDA granted it to Lu-PSMA-617, an investigational radioligand therapy to treat metastatic castration-resistant prostate cancer.
Novartis Initiates Study Evaluating Impact of Higher Dosing of Cosentyx in Patients With Ankylosing Spondylitis
The primary endpoint of ASLeap is to determine the difference between Cosentyx 300 mg and Cosentyx 150 mg at Week 52 based on the proportion of subjects achieving inactive disease status based on the ASDAS.
Important New Analysis Shows That Novartis Pharmaceutical Corporation' Entresto Is Associated With Higher Relative Health-Related Quality Of Life Scores Among HFrEF Patients
Timely Use Of Novartis Pharmaceutical Corporation' Entresto Could Prevent Or Postpone Over 28,000 US Deaths Per Year Among Hfref Patients, According To An Expert Analysis In JAMA Cardiology
Novartis Pharmaceutical Corporation To Present Pivotal Data In Hematologic And Solid Tumor Cancers At 2016 ASCO Annual Meeting
Novartis Pharmaceutical Corporation Highlights Clinical Advances At American Society of Hematology 2015, Underscoring Leadership In Hematology Research
Patients With Aggressive Form Of Melanoma Lived For More Than Two Years On Average When Taking Novartis Pharmaceutical Corporation Therapies Tafinlar + Mekinist
Novartis Pharmaceutical Corporation Announces FDA Approval For Jadenu To Simplify Treatment Administration For Patients With Chronic Iron Overload
Novartis Pharmaceutical Corporation AIN457 (secukinumab) Showed Significant Symptom Improvement In Two Pivotal Phase 3 ankylosing spondylitis Studies
Novartis Pharmaceutical Corporation To Present First IL-17A Phase 3 Data For AIN457 (secukinumab) In Psoriatic Arthritis And Ankylosing Spondylitis At ACR 2014
Novartis Pharmaceutical Corporation Release: U.S. Results From First Global Survey Of Neuroendocrine Tumor (NET) Patients Reveal Profound Impact Of This Rare Cancer On Quality Of Life
Novartis Pharmaceutical Corporation Teams Up With Multiple Sclerosis Advocate And Musician David Osmond To Launch MS Education Initiative Our Voice In Song™
SCRS Announces Novartis Pharmaceutical Corporation and Quintiles, Inc. as Winners of the 2013 Eagle Awards
AstraZeneca PLC, Pfizer Inc., Novartis Among Suitors for Onyx Pharmaceuticals, Inc.
Novartis AG Chief Touts "Industry-Best" Biosimilars
Feds Probe Novartis AG Over Marketing of Its Gilenya MS Pill
UK Health Watchdog Doesn't Recommend Novartis AG's Afinitor
Novartis Heart Drug Gets FDA's "Breakthrough" Status